Want to see HK:2289 full AI Analyst Report?
Charmacy Pharmaceutical Co., Ltd. Class H (2289) AI Stock Analysis
Top Page
Charmacy Pharmaceutical Co., Ltd. Class H
(HKEX:2289)
Overall, the stock earns a mid-range score driven by modest but stable profitability and strong recent cash generation offset by a highly leveraged balance sheet. Valuation adds support through a low double-digit P/E and a high single-digit dividend yield, while weak price trends and deeply oversold momentum indicate current market caution and technical risk.
Charmacy Pharmaceutical Co., Ltd. Class H (2289) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 592.92M
- Dividend Yield
- 6.26%
- Average Volume (3M)
- 17.00K
- Price to Earnings (P/E)
- 10.8
- Beta (1Y)
- -0.26
- Revenue Growth
- 14.25%
- EPS Growth
- 0.83%
- Country
- Hong Kong
- Employees
- 827
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Charmacy Pharmaceutical Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Charmacy Pharmaceutical Co., Ltd. serves as a prominent distributor of pharmaceutical products across the People's Republic of China. The company's comprehensive portfolio includes Western medications, traditional Chinese patent medicines, and variou...
Charmacy Pharmaceutical Co., Ltd. Class H Financial Statement Overview
Summary
Steady but low-margin earnings, high debt-to-equity with only moderate ROE, and solid recent operating and free cash flow recovery together support a mid-range financial profile.
Income Statement
56NeutralBalance Sheet
44NeutralCash Flow
63Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.68B | 4.38B | 4.44B | 4.40B | 4.18B | 3.79B |
| Gross Profit | 338.93M | 336.01M | 324.76M | 292.74M | 268.61M | 234.12M |
| EBITDA | 160.55M | 166.97M | 171.52M | 138.25M | 126.80M | 106.53M |
| Net Income | 47.11M | 46.27M | 53.28M | 51.34M | 90.47M | 23.15M |
Balance Sheet | ||||||
| Total Assets | 3.93B | 3.96B | 3.46B | 3.25B | 2.87B | 2.76B |
| Cash, Cash Equivalents and Short-Term Investments | 530.00M | 753.92M | 563.15M | 644.76M | 503.81M | 641.76M |
| Total Debt | 2.09B | 2.09B | 1.70B | 1.37B | 1.19B | 1.33B |
| Total Liabilities | 3.32B | 3.35B | 2.84B | 2.65B | 2.27B | 2.26B |
| Stockholders Equity | 606.41M | 616.63M | 618.69M | 597.81M | 594.48M | 504.10M |
Cash Flow | ||||||
| Free Cash Flow | 311.94M | 263.42M | 90.31M | -137.39M | 35.46M | -44.58M |
| Operating Cash Flow | 317.99M | 270.89M | 106.04M | -96.54M | 44.05M | -19.54M |
| Investing Cash Flow | -5.67M | -7.09M | -15.64M | 39.34M | 71.76M | -24.40M |
| Financing Cash Flow | -449.29M | -213.98M | -31.54M | 101.26M | -191.21M | 74.40M |
Charmacy Pharmaceutical Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2289, the sentiment is Negative. The current price of 5.49 is below the 20-day moving average (MA) of 5.50, below the 50-day MA of 5.50, and below the 200-day MA of 5.81, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 9.18 is Positive, neither overbought nor oversold. The STOCH value of 95.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2289.
Charmacy Pharmaceutical Co., Ltd. Class H Peers Comparison
Overall Rating
HK:219281Outperform
HK:109965Neutral
HK:260758Neutral- HK:228955.4Neutral
HK:067337Underperform
HK:193126Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2192 | 81Outperform | HKD 4.67B | 11.63 | 7.05% | 4.98% | 6.47% | 8.10% |
| HK:1099 | 65Neutral | HKD 50.52B | 6.11 | 8.33% | 4.88% | 2.78% | 7.71% |
| HK:2607 | 58Neutral | HKD 64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% |
| HK:2289 | 55Neutral | HKD 592.92M | 10.83 | 7.70% | 6.26% | 14.25% | 0.83% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:0673 | 37Underperform | HKD 360.66M | -5.29 | -273.18% | ― | 5.52% | 56.54% |
| HK:1931 | 26Underperform | HKD 575.63M | -6.46 | -2.60% | ― | -2.55% | -145.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2289 | Charmacy Pharmaceutical Co., Ltd. Class H | 5.49 | 0.38 | 7.46% | |
| HK:0673 | China Health Group | 0.26 | -0.36 | -58.06% | |
| HK:2607 | Shanghai Pharmaceuticals Holding Co Class H | 11.11 | -0.06 | -0.53% | |
| HK:1099 | Sinopharm Group Co Class H | 16.19 | -2.17 | -11.84% | |
| HK:1931 | IVD Medical Holding Limited | 0.35 | -5.93 | -94.35% | |
| HK:2192 | Medlive Technology Co., Ltd. | 6.30 | -4.03 | -38.99% |
Charmacy Pharmaceutical Co., Ltd. Class H Corporate Events
Charmacy Pharmaceutical Delivers Double-Digit Revenue Growth in First-Half 2026
Charmacy Pharmaceutical reported unaudited operating revenue of RMB 2.45 billion for the six months ended 30 June 2026, up 13.6% year on year, with total profit rising 5.9% to RMB 34.6 million. Net profit attributable to shareholders grew 3.8% to RMB...
Charmacy Pharmaceutical Sets Board Meeting to Review 2026 Interim Results and Dividend
Charmacy Pharmaceutical Co., Ltd. has scheduled a board meeting for August 31, 2026, to review and approve the interim results for the six months ended June 30, 2026. The board will also consider the declaration and payment of an interim dividend, wh...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026